Menu Search
Equities

Shanghai Haohai Biological Technology Co Ltd

SHBTF:PKC

Shanghai Haohai Biological Technology Co Ltd

Actions
  • Price (USD)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Shanghai Haohai Biological Technology Co Ltd grew revenues 25.27% from 2.10bn to 2.63bn while net income improved 130.58% from 180.47m to 416.12m.
Gross margin70.07%
Net profit margin15.45%
Operating margin19.50%
Return on assets5.81%
Return on equity7.83%
Return on investment6.86%
More ▼

Cash flow in CNYView more

In 2023, Shanghai Haohai Biological Technology Co Ltd did not generate a significant amount of cash. However, the company earned 634.45m from its operations for a Cash Flow Margin of 24.08%. In addition the company used 376.65m on investing activities and also paid 257.73m in financing cash flows.
Cash flow per share3.28
Price/Cash flow per share24.17
Book value per share26.18
Tangible book value per share21.51
More ▼

Balance sheet in CNYView more

Shanghai Haohai Biological Technology Co Ltd has a Debt to Total Capital ratio of 6.55%, a higher figure than the previous year's 3.13%.
Current ratio4.60
Quick ratio3.98
Total debt/total equity0.0746
Total debt/total capital0.0655
More ▼

Growth rates in CNY

SmartText is unavailable
Div yield(5 year avg)1.69%
Div growth rate (5 year)14.22%
Payout ratio (TTM)58.28%
EPS growth(5 years)-1.19
EPS (TTM) vs
TTM 1 year ago		71.76
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.